Evidence map›Paper›PMID 39444612›Full record

ArticleFrontiers in pharmacology2024

Fentanyl enhances immune cell response through TLR4/MD-2 complex.

Chiara Chemello, Laura Facci, Emma Marcolin, Giovanni Eugenio Ramaschi, Massimo Barbierato, Pietro Giusti, Chiara Bolego, Morena Zusso

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiara Chemello *Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Laura Facci *Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Emma MarcolinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Giovanni Eugenio RamaschiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Massimo BarbieratoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Pietro GiustiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Chiara BolegoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Morena ZussoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Opioids have been shown to induce neuroinflammation and immune cell activation, that might contribute to some of the opioid side effects, such as opioid-induced tolerance and paradoxical hyperalgesia. In this context, TLR4/MD-2 complex has been proposed as an off-target site for opioid action. This study was aimed at investigating the effect of fentanyl on lipopolysaccharide (LPS)-induced TLR4/MD-2 activation in rat primary microglia and human monocyte-derived macrophages (MDM). Materials and Methods: The effect of fentanyl was first explored by measuring the expression and release of different proinflammatory mediators in primary rat microglia and human MDM by real-time PCR and ELISA. Then, the involvement of TLR4/MD-2 signaling was investigated studying NF-κB activation in HEK293 cells stably transfected with human TLR4, MD-2, and CD14 genes (HEK-Blue hTLR4 cells) and in human MDM. Results: Fentanyl increased mRNA levels, as well as the LPS-induced secretion of proinflammatory mediators in primary microglia and MDM. Two inhibitors of TLR4/MD-2 signaling, namely the oxazoline derivative of Discussion: These results provide new insight into the mechanism of the proinflammatory activity of fentanyl, which involves the activation of TLR4/MD-2 signaling. Our findings might facilitate the development of novel inhibitors of TLR4/MD-2 signaling to combine with opioid-based analgesics for effective and safe pain management.

Indexed as

fentanylinflammatory cytokinesmacrophagesmicrogliaTLR4/MD-2 complex

Identifiers

PMID39444612
PMCPMC11496304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.